As your cell and gene therapies move from early-phase clinical trials to commercialization, your supply chain complexity—and risk—increases. Anticipating setbacks and planning for their solution requires a specialized and collaborative approach with your supply chain partner.
During this on-demand webinar, you’ll hear from industry experts who offer insights into developing a commercial supply chain for emerging autologous and allogeneic therapies.
Get insights into:
- Proven supply chain strategies that have supported the successful commercial launch of cell and gene therapies
- Keys to forming and maintaining successful collaborations in cell therapy starting material procurement and management
- The importance of leveraging partners that have historical expertise and offer comprehensive support across the commercial supply chain
- Decisions made during clinical development to help anticipate challenges at each phase of advancement and streamline commercialization
Panelists
Chris McClain, MBA
Senior Vice President, Sales & Business Development
NMDP BioTherapies (formerly Be The Match BioTherapies)
Aileen Baquiran
Vice President, Global Supply Chain and Business Operations
Orchard Therapeutics
View webinar
